Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XALL Authorized share increase
$XALL
_____________________________
If Mr. Nash can slowly sell the new 3B shares over
the next 3 years at, say $0.0020 share, he can bag
3,000,000,000 X $0.002 = $6,000,000 or $2MM per year.
__________________________________________
That's good money just for evading HD2001
______________________________________________________
$XALL
$SVRE - news update
$SVRE - alerts page
_____________
Watch for more updates:
Please Read the Full Profile Here: https://insiderfinancial.com/newalert
_______________________
$SVRE *** SVRE *** $SVRE *** $SVRE *** $SVRE *** $SVRE *** $SVRE
SVRE - preliminary program
$SVRE + Gruppo Autostrade
$SVRE
_____________
New : (NASDAQ: SVRE)
The pilot will involve the integration of SaverOne’s Driver Distraction Prevention System (DDPS) into an initial 10 vehicles within Tecne Autostrade’s fleet, which encompasses approximately 3,000 vehicles, signifying strong potential for SaverOne.
~4,300 SYSTEMS HAVE BEEN ORDERED BY CUSTOMERS
~4X (286%) YEAR-OVER-YEAR GROWTH IN REVENUE T0 $399K IN THE FIRST HALF OF 2023
SAVERONE SYSTEM INSTALLED ON 30 DELIVERY TRUCKS OF TEMPO BEVERAGES- ISRAEL’S LEADING BEVERAGE COMPANY.
_______________________
$SVRE *** SVRE *** $SVRE *** $SVRE *** $SVRE *** $SVRE *** $SVRE
SVRE - profile feature
$SVRE
_____________
NEW PROFILE IS: (NASDAQ: SVRE)
~4,300 SYSTEMS HAVE BEEN ORDERED BY CUSTOMERS
~4X (286%) YEAR-OVER-YEAR GROWTH IN REVENUE T0 $399K IN THE FIRST HALF OF 2023
SAVERONE SYSTEM INSTALLED ON 30 DELIVERY TRUCKS OF TEMPO BEVERAGES- ISRAEL’S LEADING BEVERAGE COMPANY.
_______________________
$SVRE *** SVRE *** $SVRE *** $SVRE *** $SVRE *** $SVRE
$SVRE
SVRE - 6K discloses pilot program (Italy) with Tecne Autostrade
_______________________________________
$SVRE
SVRE bags transport fleet
$SVRE
____________________________
$SVRE
_____________________________________
'SaverOne 2014 Ltd (NASDAQ: SVRE) bagged a deal with Electra Afikim to install the SaverOne system across its entire fleet of public buses, amounting to approximately 1,200 vehicles.
The financial terms of the contract remain undisclosed. Installations will likely begin in the coming weeks.
SaverOne looks to install its safety system on all the buses of Electra Afikim over the coming months.
The SaverOne system affects only the driver's mobile device during a journey and temporarily blocks all distracting applications and messaging while allowing applications that are not considered distracting or valuable for driving, as per the company's safety policy.'
FLOAT: 5,556,179
_________________________________________
$svre *** $svre *** $svre *** $svre *** $svre
$SVRE update-
$SVRE
_____________________________
Founded in 2014 with a mission to make roads safer for drivers, passengers, and pedestrians alike, SaverOne develops cellular network-based technological solutions for reducing road accidents.
Our innovative system for identifying and limiting the use of certain apps on mobile devices while operating a vehicle has already been widely adopted by dozens of companies in Israel.
SaverOne is also developing an additional system that can detect and warn the driver of VRU’s (Vulnerable Road Users and pedestrians) crossing when the driver’s field of vision is extremely limited. This system is currently in advanced stages of development.
Located in Israel, the company currently employs over 40 employees in its research and development, sales, business, operations, and support departments. Traded on NASDAQ
Traded on NASDAQ since 2020 (TASE: SVRE Nasdaq: SVRE)
SVRE touched bottom
$SVRE
----------------
1. MACD rising above signal line.
2. Money flow index sloping positive
--------------------------------------
$SVRE
$SVRE turning up
$SVRE
---------------------------
Our innovative system for identifying and limiting the use of certain apps on mobile devices while operating a vehicle has already been widely adopted by dozens of companies in Israel.
SaverOne is also developing an additional system that can detect and warn the driver of VRU’s (Vulnerable Road Users and pedestrians) crossing when the driver’s field of vision is extremely limited. This system is currently in advanced stages of development.
$SVRE
______________________________________
Systems ordered/installed 11/212023 year to date.
_______________________________________
$SVRE
Earnings increase
$SVRE
- 4X (286%) year-over-year growth in revenue to $399K during first half.
__________________________________________
$SVRE
Too many variables EEENF
$EEENF
ASX has sent me 10 announcements from
88 Energy. After the first few, the rest were
just skimmed and they were too long with
information that sounded like uncorroborated
estimates -- not facts. Too fluffy - like the
stuff from the last 4 years.
Too many questions here.
Issuing new 325,000,000 tranche
$EEENF
_________________________
Here's the EEENF - Ashley Gilbert gang in the Subiaco, WA
Australia home office after issuing another 325,000,000
'fully paid' ordinary shares......
_____________________________________________________________
After this, how many more shares to dump?
Only the Riddler knows...............
$NNVC
_______________________
$NNVC - Chart has plenty of room above to make gains. Low float remains
favorable feature here
$NNVC
______________________________________
NV-387 IS HIGHLY ACTIVE AGAINST TESTED CORONAVIRUSES INCLUDING SARS-COV-2 IN PRE-CLINICAL STUDIES
THE ENTIRE FLOAT ON NNVC IS JUST 11.2 MILL ACCORDING TO FINVIZ!
******NanoViricides, Inc. is possibly one of the few laboratories in the world to have developed an orally effective nanomedicine.
______________________________________________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
NMTC - proprietary assets
$NMTC
_______________________________
Financial Highlights:
Product revenue of $630,000 in Q3 2023, compared to $32,000 in Q3 2022
Collaboration revenue of $1.46 million in first nine months of FY 2023, compared to $6,000 in first nine months of FY 2022
Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023
Evo® sEEG:
Completed limited launch at target centers by end of July; full launch with Zimmer Biomet expected by end of fiscal fourth quarter
Positive user feedback received on product evaluation forms
Initiation of new sites expected to ramp in fiscal fourth quarter
Received first order for calendar 2024 product supply from Zimmer Biomet
OneRF™Ablation:
Submitted 510(k) to FDA on June 8th
Poster presentation on OneRF Ablation System preclinical study at the Neurological Disorders Summit (NDS 2023) in Italy
Received feedback from FDA regarding 510(k) submission for OneRF Ablation System
Spinal Cord Stimulation Program:
Completed 28 day animal implants of the Company’s thin film spinal cord stimulation paddle electrodes without any adverse events or neurological complications
Filed a non-provisional patent for a novel conformable thin film paddle lead for spinal cord placement
Drug Delivery Program:
Successfully completed proof of concept testing of drug delivery into the brain in a small animal model at the Mayo Clinic in Rochester, Minnesota
OTHER CATALYSTS
1. Disruptive next-generation diagnostic electrodes advancing a new era in neuroscience; foundational technology initially developed in collaboration with Mayo Clinic, a shareholder of the Company.
2. Strategic partnership with Zimmer Biomet (NYSE:ZBH, ~$27B mkt cap) to exclusively commercialize and distribute EVO® diagnostic electrodes; accelerated payment of $3.5 million received in August 2022.
3. Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
4. Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
______________________________________________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** NMTC ***NMTC
$NNVC
_____________________________
NEW ERA IN TARGETED ANTI-VIRAL THERAPEUTICS
NanoViricides, Inc. is a globally leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
Bullish
BULLISH
NNVC - opinion
_____________________________
$NNVC NanoViricides Inc
______________________________________________
"You are definitely going to want to keep an eye on NNVC this week.
It has a fairly low float of just 11.2Mill according to Finviz and the chart shows some wild volatile rides.
NNVC has showed that when it gets moving it can pick up steam.
Research this one right now and watch it heading into the close.
Please Read the Full Profile Here: https://insiderfinancial.com/newalert
Sincerely,
The Editor
Financial Insider
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
Good find
Thanks, loanranger!
__________________
$NNVC
NNVC - news
_____________________________
$NNVC NanoViricides Inc
08:00 PM. 11/14/1023 From Financial Insider:
Hello Everyone,
"Yesterday at 2 p.m. we sent you our full profile on $NNVC.
"It exploded to 1.33 this morning and could possibly retest those highs as it is sitting right below it as we speak.
We saw an average trade yesterday of 1.16.
It was sitting around 1.07 when we released the profile at 2pm and traded as high as 1.24.
This was another strong double digit move overnight."
_________________________________________________________________
NNVC - news
_____________________________
$NNVC NanoViricides Inc
________________________________________________
CURRENT Ratings
****Strong Buy
Based on 1 analyst(s)
source: https://www.barchart.com/stocks/quotes/NNVC/sec-filings
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
____________________________________________________________________________
$NNVC - addendum
_____________________________
$NNVC NanoViricides Inc
*******
The company released significant news this morning.
BROAD-SPECTRUM ANTIVIRAL NV-387 (NV-COV-2) IN PHASE 1A/1B CLINICAL TRIAL IS HIGHLY EFFECTIVE IN AN ANIMAL MODEL FOR MPOX AND SMALLPOX DRUG DEVELOPMENT
________________________________________________
CURRENT Ratings
****Strong Buy
Based on 1 analyst(s)
source: https://www.barchart.com/stocks/quotes/NNVC/sec-filings
__________________
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
NNVC update pending
$NNVC
_______________________________
NEW PROFILE DROPPING TONIGHT AT 8 P.M. Haven't a clue what it can be but will post tonight with a link.
(2 day chart)
______________________________________________________________
______________________________________________________________________________________
Hello Everyone,
Yesterday at 2 we sent you our full profile on NNVC.
It exploded to 1.33 this morning and could possibly retest those highs as it is sitting right below it as we speak.
We saw an average trade yesterday of 1.16.
It was sitting around 1.07 when we released the profile at 2pm and traded as high as 1.24.
This was another strong double digit move overnight.
The company released significant news this morning.
-Insider Financial
_________________________________________________________________
Hopefully this is something significant.
__________________________________________________________________
$NNVC *** NNVC *** NNVC
Another issue of shares
$EEENF
Old habits never die. At least they discovered some oil in the Permian Basin
of TX (even if it was already in barrels once they got there!).
______________________________________________
$NNVC - revised profile
$NNVC - profile update out tonight
on Insider Financial (8 PM), ready for tomorrow's open.
$NNVC - article
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
$NNVC - feature
$NNVC - article
_________________________________
Financial Insider opens coverage of
$NNVC today
_________________________________
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
$NNTC
Chart pattern predictability...
_________________________________
$NNTC reached almost $1.60 on 07/11/2023. As pharmas/biotechs are now of interest,
this ticker can jump +40% in 1 or 2 sessions.
________________________________________________________________
NNVC - 11/14/2023
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
$NNVC - Prospects
$NNVC
Re: Your post
Sound reasoning regarding the company's ultimate prospects. Well stated.
________________________________
$NNVC ***
$NNVC - PPS
$NNVC
Recent News - AUG 04, 2023 (MarketWire)
Shares of NanoViricides Inc. jumped 41.8% in premarket trading on Thursday after the company said it began developing a monkeypox treatment.
-------------------------
Past is prologue
---------------------------
$NNVC - PPS
$NNVC
Recent News - AUG 04, 2023 (MarketWire)
Shares of NanoViricides Inc. jumped 41.8% in premarket trading on Thursday after the company said it began developing a monkeypox treatment.
-------------------------
Past is prologue
---------------------------
$NNVC - PPS
$NNVC
Recent News - AUG 04, 2023 (MarketWire)
Shares of NanoViricides Inc. jumped 41.8% in premarket trading on Thursday after the company said it began developing a monkeypox treatment.
-------------------------
Past is prologue
---------------------------
NNVC - 11/13/2023
$NNVC - Low Float
_____________________________
NNVC NanoViricides Inc
Ratings Breakdown
__________________________
Based on 1 analyst(s)
1. 3 MTH AGO *** BUY
Based on 1 analysts
*******
2. CURRENT
****Strong Buy
Based on 1 analyst(s)
source: https://www.barchart.com/stocks/quotes/NNVC/sec-filings
__________________
(11/07/2023) 8K filing
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
NNVC - watching
$NNVC - views
_____________________________
NNVC NanoViricides Inc
StockTwits
https://stocktwits.com › Symbol NNVC
NNVC NanoViricides Inc. 13,127. Buy. $1.07. $0.01. (0.94%). Today. Watchers, 13,127. 52-Wk Low, $1.02. 52-Wk High, $2.00. Market Cap, $12.45M.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
NNVC - 11/13/2023 catalysts
$NNVC - Low Float
_____________________________
Low float - 11.7 milly.
******NanoViricides, Inc. is possibly the first laboratory in the world to have developed an orally effective nanomedicine.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
$NNTC - volatility
NNVC - price movement
$NNVC - 11/13/2023
__________________
History of volatility repeated 4 times at this 52 week low in prior 12 month period
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
NNVC - discussion
$NNVC - 11/13/2023 text release
$NNVC
__________________
NANOVIRICIDES TREATMENT FOR RSV
NanoViricides (NYSE American: NNVC), a leading developer of antiviral treatments through its nanomedicines platform, is developing a safe and effective alternative therapeutic for RSV. Its drug candidate, NV-387, has already been shown to not have the toxicity or side effects associated with Ribavirin, according to the company. It reports that in the recent pre-clinical animal study, NV-387 almost matched the efficacy of Ribavirin with no toxicity. This animal study was designed to mimic the lethal lung pneumonia in infants caused by RSV infection.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
NNVC - features
NNVC - 11/13/2023 catalysts
$NNVC
__________________
NV-387 IS HIGHLY ACTIVE AGAINST TESTED CORONAVIRUSES INCLUDING SARS-COV-2 IN PRE-CLINICAL STUDIES
THE ENTIRE FLOAT ON NNVC IS JUST 11.2 MILL ACCORDING TO FINVIZ!
******NanoViricides, Inc. is possibly one of the few laboratories in the world to have developed an orally effective nanomedicine.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
NNVC - 11/13/2023 catalysts
$NNVC
__________________VIRAL THERAPEUTICS_______________
NOTEWORTHY CATALYSTS
1. Broad-Spectrum, Pan-Coronavirus Drug NV-CoV-2 (API NV-387) for COVID, certain cases of long COVID, Seasonal Coronaviruses, MERS is in Clinical Trials. Two formulaJons are in clinical trials at present: Oral Syrup which can be titrated for body weight and is therefore preferable in pediatric seeng, and Oral Gummies, a fixed strength dosage form generally preferable for adults. We believe they would be highly effecJve for mild-to-moderate (non-hospitalized) cases of COVID. AddiJonally, NV-CoV-2 Solu=on for Injec=on, Infusion, and Inhala=on is developed for hospitalized COVID patients with severe disease; direct lung inhalaJon should provide significantly superior benefits by providing high pulmonary local concentration of the drug. NV-CoV-2 (NV-387) was found to have strong effectiveness in mulJple coronaviruses in vitro, and also strong effectiveness even when compared to remdesivir in animal studies of lethal lung infecJon. We believe the human clinical trial results should be consistent with these pre-clinical studies, and if so, would establish NV-CoV-2 as perhaps the most effecJve COVID treatment. There is no safe and effecJve COVID drug that covers all the paJent populaJons and disease severiJes at present, indicating significant unmet medical needs.
2. NV-387 Expanded Indications Program. We are elucidating the breadth of the anJviral spectrum of NV-387 at present. NV-387 is based on mimicking sulfated proteoglycans to a_ack the virus parJcle. A large number of viruses bind to such structures before gaining cell entry, including RSV, human MetaPneumoVirus (hMPV), certain Adenoviruses, other respiratory pathogens, as well as a number of systemic viruses such as Dengue viruses, Chickengunya, among others. Successful addiJonal indicaJons against any such viruses, if any, would significantly improve the return on investment, while fulfilling unmet medical needs.
3. Such additional indications would be eligible for Phase II/III studies with NV-387 having completed Phase I studies already.
4. Additonally, NV-387-R Could Result in Potential Cure Against a Number of Non-Latency Viruses.
HerpeCideTM Program. Variants of NV-HHV-101 are expected to become clinical drug candidates for topical treatment of HSV-2 “genital ulcers”, and HSV-1 “cold sores” soon aqer NV-HHV-101 goes into clinical studies. NV-HHV-101 is anJcipated to further expand into additional indications against chickenpox – a possibly orphan drug in the USA – and PHN (a morbidity of shingles persistent pain that may last for six months or longer, aqer the rash resolves).
We are also developing drugs against HIV.
******NanoViricides, Inc. is possibly the first in the world to have developed an orally effective nanomedicine.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
$NNVC - 11/13/2023 update
$NNVC
_____________________________
NEW ERA IN TARGETED ANTI-VIRAL THERAPEUTICS
NanoViricides, Inc. is a globally leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC